Inspire
🇺🇸 NYSE:INSP
•
Dec 31, 2024
Inspire Q4 2024 Earnings Report
Key Takeaways
Inspire Medical Systems reported strong Q4 2024 results, achieving $239.7 million in revenue, a 25% year-over-year increase. Net income rose significantly to $35.2 million, with a diluted EPS of $1.15. Operating income surged to $31.9 million, supported by an 85.0% gross margin. The company activated 72 new U.S. centers and added 12 new sales territories, contributing to growth momentum.
Inspire Revenue
Inspire EPS
Inspire Revenue by Geographic Location
Forward Guidance
Inspire expects continued growth in 2025, projecting revenue between $940 million and $955 million, reflecting 17-19% year-over-year growth. Diluted EPS is forecasted between $2.10 and $2.20, with gross margins anticipated in the 84-86% range.
Positive Outlook
- Revenue guidance increased to $940M-$955M for FY 2025.
- Expected EPS growth to $2.10-$2.20.
- Continued expansion with new sales territories and centers.
- Strong demand for Inspire V therapy driving adoption.
- Stable gross margin projection between 84-86%.
Challenges Ahead
- Increased operating expenses due to expansion efforts.
- Potential headwinds from regulatory changes.
- Macroeconomic uncertainty may impact demand.
- Stock repurchase program could impact liquidity.
- Competitive pressures in the sleep apnea market.
Revenue & Expenses
Visualization of income flow from segment revenue to net income